Background. The Acute Dialysis Quality Initiative (ADQI) XI Workgroup has suggested defining heart failure (HF) in patients with end-stage renal disease by the presence of at least one out of eight predefined echocardiographic criteria. Given the high prevalence of echocardiographic alterations in chronic kidney disease (CKD) patients, we hypothesized that application of echocardiographic ADQI criteria will result in overdiagnosis of HF, without providing substantial prognostic information. Methods. Among 472 CKD stage G2-G4 patients recruited in the CARE FOR HOMe study, we assessed the presence of leftventricular (LV) hypertrophy, valvular dysfunction, high left-atrial volume index (LAVI), systolic and diastolic LV dysfunction, enlarged LV diameter, and altered regional LV wall contractility. According to the ADQI proposal, presence of one or more of these alterations defined HF. We followed all patients for the occurrence of cardiac decompensation, defined as hospital admission for decompensated HF. Results. A total of 313 (66%) out of 472 patients fulfilled at least one ADQI echocardiographic criterion for HF. Echocardiographic alterations were more common in advanced (G3b/G4: 80%) than in milder (G2/G3a: 56%) CKD. Within subcategories of echocardiographic criteria, an increased LAVI (50%) and diastolic dysfunction (30%) were the most frequent findings. During follow-up of 4.3 6 2.0 years, the majority (87%) of all 313 patients who fulfilled ADQI echocardiographic criteria were not hospitalized for cardiac decompensation. Conclusions. Echocardiographic criteria proposed by ADQI as a precondition for the clinical staging of HF are virtually omnipresent among CKD patients. By labelling a majority of CKD patients as having HF, application of ADQI criteria fails to specifically identify patients at high risk for future cardiac events.
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I N T R O D U C T I O N
According to current American and European guidelines, symptom-based New York Heart Association (NYHA) classification is the cornerstone for grading heart failure (HF) and for tailoring cardioprotective interventions [1, 2] . This functional classification is based upon the degree of dyspnoea and other symptoms caused by ordinary physical activity [3] , and has been validated in various disease conditions, including chronic kidney disease (CKD) patients on chronic dialysis treatment [4] .
It has recently been objected that, compared with non-CKD patients, dyspnoea is more variable in CKD patients, who are often volume-overloaded, and some of whom suffer repetitive nonphysiological changes in volume balance due to intermittent dialysis treatment [5] .
Hence, the Acute Dialysis Quality Initiative (ADQI) workgroup proposed a new classification of HF for patients with end-stage renal disease (ESRD), according to which HF is defined by the presence of at least one of eight echocardiographic alterations-namely left-ventricular (LV) hypertrophy, increased LV volume, left-atrial (LA) enlargement, LV diastolic dysfunction, valvular disease, right-ventricular systolic dysfunction, LV systolic dysfunction and LV regional wall motion abnormality. In all patients meeting one or more of those echocardiographic criteria, HF class is subsequently defined by the degree of dyspnoea and by the response of congestive symptoms to renal replacement therapy and ultrafiltration [5] .
However, echocardiographic alterations are very common even in asymptomatic CKD patients [6] . Accordingly, a recent large retrospective cohort study from the Mayo Clinic Dialysis Services among incident ESRD patients found 9 out of 10 dialysis patients to fulfil at least one echocardiographic ADQI criterion, even though the presence of such alterations had limited prognostic implications [7] . We now hypothesize that even at less advanced CKD stages, a majority of patients has echocardiographic alterations that define ADQI HF, many of whom will have no cardiac events in the following years. If this hypothesis holds true, application of echocardiographic ADQI criteria in daily clinical practice will result in overdiagnosis of HF among CKD patients, while having limited value for identifying CKD patients at highest risk for cardiac events.
M A T E R I A L S A N D M E T H O D S

Study participants
Between 2008 and 2015, our ongoing CARE FOR HOMe (Cardiovascular and Renal Outcome in CKD 2-4 PatientsThe Fourth Homburg evaluation) study recruited 544 patients with CKD G2-G4 [defined as an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m 2 and 89 mL/min/1.73 m 2 using the four-variable Modification of Diet in Renal Disease equation [8] ]. All participants signed their informed consent for baseline and follow-up examinations. The study was approved by the local ethics committee and was conducted in concordance with the Helsinki Declaration.
We excluded patients with an acute kidney injury (defined as increase of plasma creatinine >50% within 4 weeks), systemic immune suppressive medication, human immunodeficiency virus infection, acute infectious disease [defined as need for requiring systemic antibiotic therapy and/or C-reactive protein (CRP) levels >50 mg/L] or active cancer disease. Further exclusion criteria were need for renal replacement therapy, pregnancy and age <18 years.
To validate our echocardiographic studies in comparison with results from the Mayo Clinic Dialysis Services, we additionally examined 39 ESRD patients who undergo chronic hemodialysis treatment, comprising six patients who earlier participated in the CARE FOR HOMe echocardiography study.
Baseline examination
We used a standardized questionnaire to record cardiovascular comorbidity (defined as a history of myocardial infarction, coronary artery angioplasty/stenting/bypass surgery, major stroke, carotid endarterectomy/stenting, nontraumatic lower extremity amputation or lower limb artery bypass surgery/ angioplasty/stenting), prevalent diabetes mellitus, current drug intake, a history of smoking and family history of premature cardiovascular events. Moreover, comorbidity was assessed by means of chart review. Patients with self-reported diabetes mellitus, with a fasting blood glucose level of at least 126 mg/dL and/or current use of hypoglycaemic medication were categorized as diabetic. Subjects were categorized as active smokers if they were current smokers or had stopped smoking <1 month before entry into the study.
We measured weight and height in all patients. Body surface area (BSA) was estimated as [(height (cm) Â weight (kg))/ 3600] 0.5 [9] , and body mass index (BMI) was calculated as
Blood samples were obtained under standardized conditions after an overnight fasting and after 5 min of resting. Plasma levels of amino-terminal pro-brain natriuretic peptide (NTproBNP), creatinine (traceable to IDMS), glucose and CRP were measured using standard methods.
Echocardiographic measurements
Echocardiographic measurements were performed by a single operator from standard parasternal and apical view, using a Sequoia C512 ultrasound unit (Acuson, Thousand Oaks, CA, USA) with a linear probe (model 3V2c, 2-3 MHz). All echocardiographic studies followed the guidelines of the American Society of Echocardiography (ASE) [10] .
LV mass (LVM) and LA volume (LAV) were determined by using the formula suggested by ASE guidelines [10] :
]] þ 0.6 g, where LVD is the LV diameter at end diastole and PWT/SWT are posterior and septal wall thickness at end diastole.
, where A1 is the LA area in an apical four-chamber view, A2 the LA area in an apical twochamber view and L the shorter LA length measured from the back wall to line across the hinge points.
Dividing LVM and LAV by BSA yielded the LVM index (LVMI) and LAV index (LAVI), respectively, which account for variations in body size.
As parameter of diastolic LV function, we calculated E/e 0 by building the ratio between early diastolic mitral inflow velocity (E, assessed with pulsed wave Doppler ultrasound) to early diastolic septal mitral annular velocity (e 0 , assessed with tissue Doppler recording).
We assessed systolic LV function as endocardial fractional shortening (FS) and by visual inspection. In general, we considered FS <28% as impaired LV function; biplane ejection fraction was not measured in the majority of patients.
LV regional wall motion abnormalities were assessed by visual inspection. Valvular diseases were classified as mild, moderate or severe, as suggested by ASE recommendations.
The current analyses include 472 CARE FOR HOMe participants who were recruited after 25 November 2008 and who had a baseline echocardiography. 48 patients had no baseline echocardiography (mainly for organizational reasons, particularly the unavailability of the operator who performed echocardiography). We further excluded 24 patients recruited until 25 November 2008, when echocardiographic studies were less comprehensive than afterwards and did not include standardized assessment of left atrial volume and diastolic LV function ( Figure 1 ).
Outcome
ADQI HF was diagnosed in patients who fulfilled at least one echocardiographic ADQI criterion. To assess the occurrence of our predefined primary endpoint cardiac decompensation, defined as hospital admission for decompensated HF, all patients were invited to annual follow-up visits in our outpatient clinic until they became dialysis-dependent. If appearance in person was not possible, we contacted the patients or their next of kin for a telephone interview. If the patient had become dialysis-dependent after study initiation, we contacted the treating dialysis centre as well as the patient or his/her next of kin. We defined decompensated HF as admission for a clinical syndrome involving symptoms (progressive dyspnoea) in conjunction with radiological (cardiomegaly, pulmonary oedema, pleural effusions) and/or clinical (peripheral oedema, pulmonary rales) signs. All events were verified by medical reports from the treating physician, and adjudicated by two independent physicians blinded for baseline echocardiographic and clinical data. In case of disagreement, the final decision was made by a third physician. As a secondary endpoint, we analysed the combined endpoint of cardiac decompensation, as defined above, and cardiovascular death, following the American College of Cardiology/American Heart Association Key Data Elements and Definitions for Cardiovascular End point Events in Clinical Trials [11] .
For the present analyses, patients were followed until December 2015. Four patients refused to provide updated clinical information; follow-up data for the 468 remaining patients were completed. Vital status was known for all patients in December 2015.
Statistical analyses
Continuous data are presented as means 6 standard deviation, or median [interquartile range (IQR)] for nonnormally distributed variables, and compared using a t-test for independent samples, while categorical variables are expressed as a percentage of participants and compared using Fisher's test.
To account for differences in the follow-up period, we estimated sensitivity, specificity, positive and negative likelihood ratios (LRþ and LR-) [12] , positive and negative predictive values of ADQI HF to predict cardiac endpoints during the first 3 years of follow-up among all patients who had informative 3 years of follow-up.
We used Kaplan-Meier analyses to calculate the event-free survival probabilities, which were compared using the log-rank test and plotted in survival diagrams.
To assess the associations between the presence of ADQI HF and cardiac outcome independently of traditional cardiovascular risk factors, cardiovascular comorbidity and CKD stages, we used multivariable Cox models adjusting for age, gender, current smoking, diabetes mellitus, prevalent cardiovascular disease (CVD) and eGFR.
R E S U L T S CARE FOR HOMe patients
The 472 study participants included in the present analysis had a mean age of 65 6 12 years and a mean eGFR of 47 6 16 mL/min/1.73 m 2 . Median NT-proBNP was 208 (IQR 89-589) pg/mL. Further baseline characteristics are given in Table 1 .
Among the 472 CKD patients recruited, 313 (66%) had at least one of the echocardiographic alterations which conformed to the diagnosis of HF by ADQI. The most frequent alterations were increased LAVI (50%), followed by diastolic dysfunction (30%). The proportion of patients with ADQI HF was higher among patients with more advanced CKD (G3b/G4: 80%) than among patients in milder CKD stages (G2/G3a: 56%; Table 2 ).
Patients who were classified as affected by HF according to ADQI had higher age, more prevalent CVD and a worse kidney function. Further, NT-proBNP differed significantly between patients with ADQI HF [336 (138-894) pg/mL] and patients without ADQI HF [95 (45-165) pg/mL; Table 3 ].
During a mean follow-up of 4.3 6 2.0 years, 43 patients were admitted to hospital for cardiac decompensation. In all, 26 out of these 43 events occurred within the first 3 years of follow-up.
As expected, patients who suffered cardiac decompensation during follow-up were older, had a higher prevalence of CVD and lower eGFR at baseline. Moreover, they had higher NTproBNP [1340 (547-2972) pg/mL] than patients who did not suffer cardiac decompensation [175 (78-420) pg/mL] during follow-up (Table 1) .
Furthermore, patients suffering cardiac decompensation had higher LVMI, LAVI, LV diastolic diameter and E/e 0 , and were more likely to have valvular disease, impaired systolic LV function and/or LV regional wall motion abnormalities at baseline (Table 1) .
Even though the presence of ADQI HF was associated with more cardiac events during follow-up (Figure 2 ), the majority (87%) of CKD patients met ADQI HF definition did not suffer cardiac decompensation during follow-up.
The sensitivity (96%), the negative predictive value (99%) and the LR-(0.1) of ADQI HF criteria for predicting cardiac decompensation during 3 years of follow-up were good, but specificity (37%), the positive predictive value (11%) and the LRþ (1.5) were poor.
Similarly, ADQI HF predicted the combined endpoint of cardiac decompensation/cardiovascular death ( Figure 2 ) and had good sensitivity (95%), negative predictive value (98%) and Echocardiographic heart failure classification in CKD LR-(0.1) for 3-year event rate, but again specificity (37%), positive predictive value (16%) and LRþ (1.5) were poor.
When analysing each echocardiographic criterion separately, no single parameter has a reasonable performance as predictor for future cardiac events (Supplementary Table S1 and S2).
Moreover, we analysed two modified versions of the ADQI classification that defined HF in patients who meet (i) at least two echocardiographic criteria or (ii) at least three echocardiographic criteria (Supplementary Figure S1 , Tables S1 and S2). These modified definitions increased specificity while decreasing sensitivity. However, the overall test performance remained poor.
In 
Dialysis patients
In all, 36 out of 39 dialysis patients (92%) fulfilled at least one echocardiographic ADQI HF criterion. Similar to CARE FOR HOMe patients, the most common echocardiographic alterations among dialysis patients were an increased LAVI (80%) and diastolic dysfunction (41%; Table 4 ).
D I S C U S S I O N
CKD patients have a very high prevalence of myocardial disease, which substantially contributes to their extraordinarily high morbidity and mortality [13] . Early diagnosis of HF may allow identification of those CKD patients at particular risk for cardiac decompensation and cardiovascular death, who may specifically profit from intensive pharmacological cardioprotective treatment.
In the general population, diagnosis of HF is based upon clinical signs and symptoms, measurements of natriuretic peptides and echocardiographic studies [2] . Patients who fulfill diagnostic HF criteria should next be graded according to NYHA functional classification, which is based upon the degree of dyspnoea and other symptoms caused by ordinary physical activity [3] , and upon which evidence-based therapeutic strategies are tailored.
For various reasons, application of these diagnostic strategies is more challenging in CKD: accumulation of natriuretic peptides may impede their interpretation in patients with reduced renal function [14, 15] , and the cardinal symptom of HF, dyspnoea, may result from volume overload rather than from cardiac disease in these patients [5] . In advanced CKD patients needing renal replacement therapy, repetitive nonphysiological changes in volume balance due to intermittent dialysis treatment with ultrafiltration further hampers the interpretation of dyspnoea. It has therefore been claimed that a CKD-specific classification of HF is required in advanced CKD, and the ADQI workgroup has proposed such HF definition for ESRD patients, which is based upon a rather broad spectrum of echocardiographically detected cardiac alterations. Once ESRD patients fulfill those echocardiographic criteria, they are subsequently classified according to their degree of dyspnoea and to the response of their symptoms to renal replacement therapy and ultrafiltration [5] .
However, cardiac alterations are virtually omnipresent among CKD patients, as already shown in cohort studies that had been conducted before ADQI criteria were developed [16] [17] [18] [19] [20] . While the original ADQI consensus paper provides no validation for the proposed HF criteria, Mayo Clinical Dialysis Services subsequently applied these criteria in 654 incident dialysis patients and found absence of any predefined echocardiographic alteration in only one out of eight patients, yielding a high HF prevalence of 87% among ESRD patients [7] .
We now expand these findings to a cohort of CKD G2-G4 patients who participated in our ongoing CARE FOR HOMe study, and found that even in the context of less advanced CKD, two out of three patients fulfill echocardiographic ADQI HF criteria. In exploratory studies, we additionally analysed a small cohort of dialysis patients, and found a prevalence of ADQI HF virtually identical to the large Mayo Clinic Dialysis Services cohort.
Consistency of our data with findings from the Mayo Clinical Dialysis Services data is further substantiated by the distribution of echocardiographic alterations, among which increased LAVI [81% (Mayo Clinic Dialysis Services), 80% (Homburg dialysis patients) and 50% (CARE FOR HOMe)], diastolic dysfunction (78%, 41% and 30%, respectively) and LV hypertrophy (49%-71%, 36% and 12% respectively) were the most frequent echocardiographic alterations.
For methodological reasons, the high prevalence of ADQI HF among CKD patients will eventually impede discrimination of those patients who will suffer a cardiac event in the foreseeable future from patients with event-free survival. Accordingly, in the Mayo Clinic Dialysis Services cohort, mortality did not differ between patients with ADQI HF (defined by the presence of one or more echocardiographic HF criteria) from patients without ADQI HF (defined by the absence of any predefined echocardiographic alteration). Even a more stringent HF definition (presence of two or more echocardiographic criteria) predicted worse outcome only in univariate analyses, but not after adjustment for age and gender. When analysing each echocardiographic alteration separately, only right-ventricular dysfunction and reduced LV ejection fraction independently predicted mortality after adjustment for age and gender. Analyses adjusted for various clinical confounders beyond age and gender were only available for right-ventricular dysfunction, which however was a strong outcome predictor; this finding is in line with CARE FOR HOMe study results on the prognostic implications of elevated right-ventricular systolic pressure published earlier [21] . As a limitation of the Mayo Clinic Dialysis Services, echocardiographic studies were retrospectively analysed, so that ultrasound examinations were conducted in a less standardized way than in a prospective study. Moreover, the Mayo Clinic Dialysis Services analysed a nonspecific endpoint, e.g. all-cause mortality, and it remained so far unknown whether diagnosis of ADQI HF may be a suitable predictor of more specific cardiac endpoints.
To fill this gap in knowledge, we set out to prospectively collect outcome data for the pivotal clinical endpoint in myocardial disease, e.g. admission for acute HF. Even though ADQI HF had a high sensitivity for identifying patients who suffer cardiac decompensation in the following years (which directly results from its very high prevalence among CKD patients), specificity was poor, since only one out of eight patients who fulfilled ADQI HF criteria was admitted for cardiac decompensation during the following years. Consistently, this aspect is reflected by the poor positive likelihood ratio of 1.5. Beyond their low power for outcome prediction, further limitations of an echocardiography-based HF classification comprise the restricted availability and the high operatordependency of echocardiographic studies, and the limited standardization of echocardiographic reports. This latter aspect is reflected by the variant prevalence of LV hypertrophy among Mayo Clinic Dialysis Services patients, which ranged from 49% to 71%, with different approaches for anthropometrical standardizing of LV mass. Such methodical issues may also partly account for the higher prevalence of LV hypertrophy in earlier echocardiographic studies among CKD patients [16, 20] , compared with CARE FOR HOMe.
It has been argued earlier by us that biomarkers such as plasma natriuretic peptides may outperform echocardiographic parameters for outcome prediction in routine clinical practice [22] , although renal function impairment affects plasma levels of natriuretic peptides even in the absence of overt systolic dysfunction [15] . Compared with echocardiography, measurement of natriuretic peptides is less time consuming, and better standardized, than echocardiographic studies. We however concede that, beyond the limitation of echocardiographic scores for HF definition, echocardiography will remain the cornerstone of cardiac imaging, as it allows noninvasive assessment of chamber volumes, systolic and diastolic ventricular function, wall thickness, valve function and pulmonary hypertension alterations; accordingly, routine echocardiographic studies have been endorsed by current nephrological guidelines [23] .
Finally, even though the use of NYHA classification among CKD patients has been disputed by the ADQI, earlier cohort studies showed that NYHA classes are strong and independent predictors of all-cause and cardiovascular mortality in dialysis patients [4] , which outperformed other risk-prediction instruments such as the Khan index [24] and the Renal Disease Severity Score [25] . Moreover, when applied immediately before dialysis, NYHA classification had reasonable inter-rater agreement in dialysis patients [4] . Thus, we surmise that HF in dialysis patients can be directly staged. Such an approach, which maintains a strong focus on actual symptoms, may facilitate detection of HF in clinical practice and provide a simple and reliable instrument for large epidemiological studies.
As a limitation, we did not collect data on symptoms of HF (e.g. dyspnoea); thus, we cannot classify our study participants into NYHA HF classes. Next, since we initiated the longitudinal CARE FOR HOMe study before ADQI HF criteria were published, echocardiographic criteria for the present analyses were slightly modified compared with the original ADQI proposals, and information on right systolic function is missing. Moreover, for assessment of LV function, we used endocardial FS rather than biplane ejection fraction, and LV size was assessed from LV diastolic diameter rather than from LV diastolic and systolic volume. For obvious technical reasons, similar to daily clinical practice, not all echocardiographic measurements were feasible in each patient. Finally, we deliberately expand ADQI criteria, which were initially proposed for dialysis patients, toward patients with less severe CKD, which allowed us to confirm and expand recent findings from the Mayo Clinic Dialysis Services. By doing so, we can clearly show that ADQI HF criteria will overdiagnose HF across the spectrum of CKD.
In summary, we advocate using ADQI criteria with great caution until their validity and utility have been shown in independent prospective studies. The very high prevalence of ADQI HF across the spectrum of CKD will eventually result in overdiagnosis of HF, and preclude sensible risk stratification.
S U P P L E M E N T A R Y D A T A
Supplementary data are available online at http://ndt.oxford journals.org. LV regional wall motion abnormality
Regional wall motion abnormality of LV (>10% of the myocardium)
Regional wall motion abnormality of LV (>10% of the myocardium) 15% 0%
Echocardiographic evidence of heart failure At least one abnormal echocardiographic criterion
At least one abnormal echocardiographic criterion 92% 8%
w, women; m, men; RV, right-ventricular; TAPSE, tricuspid annular plane systolic excursion. 
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